news
El Financiero
2026-10-15
Pancreatic cancer drug shows promise in clinical trials by doubling survival rates
An experimental drug called daraxonrasib has received a positive recommendation from European regulators after demonstrating the ability to significantly extend survival in aggressive cancer cases.